Bridging Rare Disease Innovation - from East to West, from Lab to Life.

Golden Age Health (GAH) is a pharmaceutical platform specializing in rare and specialty diseases, creating a vital two-way bridge for innovation. We connect the world's most advanced therapies with patients in China, while simultaneously sourcing high-potential assets from China's maturing biotech ecosystem for global development and commercialization.

Our leadership team, comprised of seasoned global pharma executives including the former CEO of Biogen and the architects behind China's most successful rare disease launch (Spinraza), possesses the deep expertise needed to navigate complex business and cultural landscapes. We excel at bridging the gap between brilliant scientist-founders and global commercial success.

We offer flexible, end-to-end partnership models that cover the full commercialization spectrum, from regulatory strategy and market access to patient engagement and real-world evidence generation. Our mission is to accelerate patient access to medical breakthroughs by cutting time-to-market, de-risking launches for our partners, and creating sustainable value for payers and investors worldwide.

“My decades of launching breakthrough therapies —from Spinraza® to Keytruda® — have taught me a simple truth: science only fulfils its promise when patients can reach it. Golden Age Health exists to collapse that distance. Together with our partners we will turn access from a slogan into a measurable outcome—months, not years — for every family we serve.”

— Michel Vounatsos, Co-founder and Executive Chairman